Formulary
Mecasermin: Indications, Dosing, Side Effects and Interactions
Mecasermin, a recombinant human insulin-like growth factor-1 (rhIGF-1), is the principal mediator of the somatotropic effects of human growth hormone.
MedNext Academy | 3 min read
Mecasermin: Indications, Dosing, Side Effects and Interactions
Mecasermin, a recombinant human insulin-like growth factor-1 (rhIGF-1), is the principal mediator of the somatotropic effects of human growth hormone.
Drug action
Mecasermin, a recombinant human insulin-like growth factor-1 (rhIGF-1), is the principal mediator of the somatotropic effects of human growth hormone.
Indications and dose
**Treatment of growth failure in children with severe primary insulin-like growth factor-I deficiency for mecasermin**
- **Child 2-17 years** (By subcutaneous injection): Initially 40 micrograms/kg twice daily for 1 week, increased, if tolerated, in steps of 40 micrograms/kg (max. per dose 120 micrograms/kg twice daily), discontinue if no response within 1 year, reduce dose if hypoglycaemia occurs despite adequate food intake; withhold injection if patient unable to eat.
Clinical governance
**Author:** MedNext Clinical Team. **Clinical reviewer:** Dr Shameer Deen, MBBS, MS, MRCS. **Sources:** BNF, Indian Pharmacopoeia, CIMS India. **Correction:** Report errors at support@mednext.academy.
Inside MedNext for this topic
- 411 MedNext-authored chapters
- 80,000+ MCQ bank
- 15 study modes
- Growing visual cheat sheets
Study modes
- Notes
- MCQ
- Audio
- Video
- Visual
- 3D Anatomy
- Trace
- Flashcards
- Mnemonics
- Image Bank
- Clinical
- Microscopy
- Audio QBank
- Cadaver
- Book Match
Continue reading
Subject HubPharmacology Hub
All pharmacology resources in one place.
Drug SchedulesIndian Drug Schedules
Schedule H, H1, X and G classifications.
FormularyBrowse all drugs
Search 1,850+ drug profiles.
Study Mecasermin in the MedNext app
Challenge yourself with targeted pharmacology MCQs on this drug class. Every explanation links back to the chapter that teaches the concept.
Start drug challengeExplore the full formulary

